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Background: Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has
either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous
alternatively spliced transcripts, which initiate from two different unique first exons within the WT1 and the
alternative (A)WT1 promoter intervals. Within the hematological system, WT1 expression is restricted to CD34+/
CD38- cells and is undetectable after differentiation. Detectable expression of this gene is an excellent marker for
minimal residual disease in acute myeloid leukemia (AML), but the underlying epigenetic alterations are unknown.
Methods: To determine the changes in the underlying epigenetic landscape responsible for this expression, we
characterized expression, DNA methylation and histone modification profiles in 28 hematological cancer cell
lines and confirmed the methylation signature in 356 cytogenetically well-characterized primary hematological
malignancies.
Results: Despite high expression of WT1 and AWT1 transcripts in AML-derived cell lines, we observe robust
hypermethylation of the AWT1 promoter and an epigenetic switch from a permissive to repressive chromatin
structure between normal cells and AML cell lines. Subsequent methylation analysis in our primary leukemia and
lymphoma cohort revealed that the epigenetic signature identified in cell lines is specific to myeloid-lineage
malignancies, irrespective of underlying mutational status or translocation. In addition to being a highly specific
marker for AML diagnosis (positive predictive value 100%; sensitivity 86.1%; negative predictive value 89.4%), we
show that AWT1 hypermethylation also discriminates patients that relapse from those achieving complete remission
after hematopoietic stem cell transplantation, with similar efficiency to WT1 expression profiling.
Conclusions: We describe a methylation signature of the AWT1 promoter CpG island that is a promising marker
for classifying myeloid-derived leukemias. In addition AWT1 hypermethylation is ideally suited to monitor the
recurrence of disease during remission in patients undergoing allogeneic stem cell transfer.
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Overexpression of the Wilms’ tumor 1 gene (WT1) is
implicated in the prognosis of leukemia with high ex-
pression predicting disease progression in acute myeloid
leukemia (AML), as well as being intensively studied as
a potential molecular marker for minimal residual dis-
ease (MRD) and treatment response. In the normal sce-
nario, WT1 expression is restricted to CD34+ cells in
the bone marrow and absent in peripheral blood cells;
therefore expression of this zinc-finger transcription fac-
tor is limited to early progenitors of the blood system,
suggesting that this gene plays a critical role in control-
ling proliferation and/or differentiation in hematopoietic
stem cells [1].
Many different isoforms exits for WT1, and it is es-
timated that it can have over 36 different isoforms ge-
nerated by alternative transcription initiation, mRNA
splicing and alternative translation initiation [2]. The
most studied and common splicing events affects exon 5
leading to the presence or absence of 17 amino acids
(+17/-17aa) and alternative-splicing within exon 9 with
the possible insertion of three amino acids (lysine, threo-
nine and serine: +KTS/-KTS), resulting in a 52-54 kDa
protein. Recently an alternative promoter incorporating
a unique first exon has been described. The alternative
WT1 transcript (AWT1) encodes a 32 kDa protein defi-
cient for the first 147 amino acids of the N-terminal of
the WT1 protein, which lacks the repressor domain and
the RNA recognition motif of the full-length protein [3].
Transcripts from this alternative promoter also undergo
splicing events leading to the +/−17aa and +/−KTS iso-
forms. In addition to these protein-coding transcripts,
an non-coding antisense transcript (WT1-AS) also origi-
nates within the ~5 kb promoter interval (Figure 1A).
Both the antisense and AWT1 transcripts have been re-
ported to be paternally expressed in kidney and blood
samples [4,5]. These transcripts originate from a region
of partial methylation, the WT1 antisense regulatory re-
gion (WT1-ARR) that has been proposed to act as a cis-
acting transcriptional silencer on the maternal allele [6].
Expression profiling of WT1 is becoming almost uni-
versal in characterizing AML. Recently, raised WT1 le-
vels at diagnosis and post-induction are associated with
poorer outcomes, whereas patients with very low WT1
level post-intensification had excellent outcomes [7]. Des-
pite aberrant expression of WT1 being a useful marker for
diagnosis and monitoring MRD in AML the underlying
epigenetic alterations associated with this expression are
unknown [8]. Using a panel of 28 hematological cancer
cell lines and more than 350 primary samples we identify
AML-specific AWT1 promoter hypermethylation that is
present irrespective of underlying translocation/onco-
genic fusion protein or mutations, which is accompa-
nied by a concomitant epigenetic switch at the levelof post-translational histone tail modifications. Finally
we show that this robust AWT1 epigenetic signature
is an excellent marker for discriminating AML from
non-diseased peripheral blood and that this hypermethyla-
tion signature can accurately track disease progression,
differentiating patients who relapse from those achieving
complete remission after allogeneic hematopoietic stem
cell transplantation (SCT).
Results
Abundant biallelic expression of the WT1/AWT1
transcripts result in nuclear retained proteins in myeloid
derived leukemic cell lines
qRT-PCR was performed on a wide range of leukemia
and lymphoma cell lines to evaluate the transcription
levels of the WT1, AWT1 and the non-coding antisense
transcript WT1-AS. In all myeloid origin cell lines evalua-
ted the WT1 and AWT1 transcripts were readily detec-
table, with high correlation (Pearson correlation, r = 0.90),
indicating that they are likely to be co-regulated. The
WT1-AS transcript was also expressed in most of the
myeloid cell lines (Figure 1B). In contrast, the majority of
B-, T- cell leukemic cell lines and lymphomas did not ex-
press these transcripts, with the exception of MOLT4 and
NALM-20, the later being a cell line with a t(9;22) trans-
location and biphenotypic B-cell and myeloid cell charac-
teristics [9]. The transcripts within the WT1 locus have
been described to be expressed from the paternal allele in
an imprinted manner [6,7]. The over-expression of these
transcripts in the cell lines allowed us to determine allelic
expression. Using primer pairs designed to distinguish in-
dividual isoforms (i.e. the forward primer was in the
unique first exon of each transcript) and incorporate SNPs
identified in the UCSC sequence browser (GRC27/hg19-
dbSNP 135) into the final RT-PCR product, we observe
that WT1, AWT1 and WT1-AS are biallelically expressed
in all heterozygous cell lines (Figure 1C). Finally, western
blotting using an antibody directed against the C-terminal
of the WT1 protein revealed that the abundant RNA
levels forWT1 and AWT1 isoforms are translated into nu-
clear retained proteins in the myeloid derived cell lines
KG1A, NB4 and K562, consistent with their transcription
factor function (Figure 1D).
AWT1 promoter hypermethylation despite over-expression
in AML
Having confirmed the high expression of WT1 and AWT1
in myeloid derived cancer cell lines we next wished
to determine if this expression profile was associated
with lineage specific DNA methylation changes. We deter-
mined the methylation profile of the WT1 5′ interval
using publically available WGBS datasets for CD34+ cells
and peripheral leukocytes (Figure 2A). In addition we
performed a specific bisulphite PCR analysis across the
Figure 1 Expression profiling of the various WT1 transcripts in leukemia cell lines. (A) Map of the WT1 locus, showing the location of the
various promoters, CpG islands and enhancer elements. Arrows represent direction of transcription. (B) Expression of WT1, AWT1 and WT1-AS in
control bone marrow and peripheral blood leukocytes compared to hematological cancer cell lines. (C) The allelic expression of the various
transcripts in expressing cell lines. (D) Western blot analysis of nuclear (N) and cytoplasmic (C) cellular fractionations reveal that the WT1 and
AWT1 proteins are nuclear retained in leukemia cell lines. Purity of the cellular fractionations was confirmed using anti-sera against Nucleolin, a
nuclear retained protein and cytoplasmic β-tubulin.
Guillaumet-Adkins et al. Journal of Hematology & Oncology 2014, 7:4 Page 3 of 11
http://www.jhoonline.org/content/7/1/4promoter interval in cell lines, peripheral blood leukocytes
and immunosorted CD15+, CD19+ and CD3+ cells.
The promoter region for WT1 is located within a CpG
island of 2.4 kb that is unmethylated in all normal
cell types as revealed by the WGBS (chr11: 32454875
32457311 = CD34+ 3% methylated; leukocytes 5% me-
thylated). Approximately 4 kb downstream in intron 1,
a second promoter region is embedded within an un-
methylated CpG island of 560 bp (chr11: 32452145-
32452708 = CD34+ 24% methylated; leukocytes 15%
methylated), giving rise to the AWT1 and WT1-AS iso-
forms (Figure 2A). Adjacent to these promoters is a region
of proposed allele specific DNA methylation, the WT1-
ARR, which has been implicated in regulating expression
of these transcripts (chr11: 32454083-32454765 = CD34+
33% methylated; leukocytes 18% methylated). Our analysisutilizing standard bisulphite PCR and subcloning of
normal leukocyte samples heterozygous for the SNP
rs11031781 revealed that this region is mosaically methy-
lated on both alleles (Figure 2B), consistent with a lack of
imprinted methylation despite normal leukocytes ha-
ving methylation on the paternal allele at the H19 loci
(Additional file 1: Figure S1A).
Methylation analysis of the entire panel of leukemia
and lymphoma cell lines, determined by pyrosequencing,
revealed that in myeloid derived cancer cell lines the
WT1 CpG island promoter is unmethylated, except for
the HL-60 cell line that was completely hypermethyla-
ted, whereas the AWT1 CpG island promoter was meth-
ylated in all cell lines evaluated. The WT1-ARR region
showed varying amounts of methylation (Figure 2C).
In B- and T-cell derived leukemic cell lines the WT1
Figure 2 (See legend on next page.)
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Figure 2 Methylation analysis in myeloid-derived cancer cell lines. (A) A detailed map of the WT1 promoter interval with the methylation
profile for CD34+ and leukocyte cells determined by WGBS. Vertical dark grey lines in the WGBS tracks represent the mean methylation value for
individual CpG dinucleotides calculated from multiple data sets, with the light grey lines representing the mean + standard deviation. The
positions of the bisulphite PCR products are indicated. (B) The methylation status of the WT1 and AWT1 promoters and the WT1-ARR region in
control leukocytes and immuno-selected cells. Each circle represents a single CpG dinucleotide on a DNA strand, a methylated cytosine (●) or an
unmethylated cytosine (ο). Allelic methylation was determined in all heterozygous samples. (C) The methylation profile in AML cell lines. (D)
Quantitative PCR on meDIP preciptations using specific antibodies against 5hmC and 5mC in three cell lines that show hypermethylation of the
AWT1 CpG island using bisulphite techniques.
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AWT1 promoter. In lymphoma cell lines, the entire locus
was fully methylated (Additional file 1: Figure S1B).
The AWT1 methylation detected by bisulphite analysis is
5mC and not 5hmC
Recently 5-hydroxymethylation (5hmC), an oxidized de-
rivative of 5-methylcytosine (5mC) has been suggested
to regulate gene expression and is moderately enriched
within CpG rich promoters and actively transcribed gene
bodies [10]. Unfortunately the deamination of unmethy-
lated cytosines that occurs during conventional bisulfite
reactions does not distinguish between 5mC and 5hmC,
therefore the bisulphite resistant cytosines we observed
in the AML cell lines may reflect enrichment of 5hmC
and not 5mC. In order to differentiate these methylation
states, we performed DNA immunoprecipitation utiliz-
ing antibodies that can discriminate 5hmC from 5mC in
the myeloid cell lines, K562, KG1A and NB4. Using this
technique we show that the methylation present at the
AWT1 promoter is 5mC (Figure 2D). We confirm these
observations using a second method utilizing a highly
specific 5hmC glucosyltransferase that tags a glucose
moiety to 5hmC but not to 5mC, rendering h5mC re-
fractory to digestion with the Glucosyl-5hmC Sensitive
Restriction Endonucleases (GSRE) enzyme (MspI-CCGG)
(data not shown).
AWT1 hypermethylation is associated with a switch from
permissive to repressed chromatin state
Using publically available ChIP-seq datasets from the
ENCODE project, we determined the histone modifica-
tion profile of H3K4me3, H3K27me3, H3K9me3 in nor-
mal CD34+ and CD15+ cells. The observed profile was
similar to that obtained in control leukocytes using ChIP
targeting the WT1 5′ interval (Figure 3A, B) suggesting
very little cell-type variation in normal blood lineages.
Unfortunately no ChIP-seq data is available for H3K4me2
for direct comparison. Subsequent experiments were
performed on the K562 and NB4 cell lines that have
methylated AWT1 promoters, unmethylated WT1 CpG
islands with high expression levels of the both transcripts.
For these cells lines, the control GAPDH promoter and
α-satellite repeat regions were normal and comparableto control leukocytes with enrichment of the active
H3K4me3 and repressive H3K9me3 marks, respect-
ively. In both cell lines there was massive abundance
of the active histone mark H3K4me3 at the WT1 pro-
moter. This represents a change from modest H3K4me2
enrichment in control leukocytes that may directly reflect
the high level of active transcription from this promoter.
The AWT1 promoter had epigenetically switched from an
unmethylated interval with H3K4me2 enrichment to
having high levels of H3K9me3 in both K562 and NB4, a
repressive mark functionally associated with DNA hy-
permethylation (Figure 3C, D) [11,12]. No H3K27me3
precipitation was observed at the AWT1 or WT1 pro-
moter regions in leukocyte or AML-derived cell lines
(Figure 3B-D).
The methylation profiles in cell lines reflect the
epigenetic state in primary AML at diagnosis
To ensure that the methylation profiles obtained in the
hematological cancer cell lines could be recapitulated
in primary hematological malignancies, we adapted our
bisulphite PCRs for quantitative pyrosequencing and as-
sessed a large cohort of cytogenetically well-characterized
samples collected at initial diagnosis. These assays gave
extremely consistent methylation values in our control
cohort with low variability (WT1 average methylation
2.4%, ± 3SD (0–7.1%); AWT1 average methylation
15.1%, ± 3SD (5.74-24.4%). However we utilized a strict
definition for hypermethylation of >40% to ensure we
identify only extreme cases of aberrant methylation. Using
this criteria the unmethylatedWT1 CpG island and hyper-
methylated AWT1 signature was extremely prevalent in
AML patients, including individuals with the recurrent ge-
netic abnormalities inv(16)(p13.1q22), t(16;16)(p13.1;q22)
CBFB-MYH11, t(8;21)(q21;p22) AML1-ETO, t(15;17)
(q22;q12) PML-RARA, t(9;11)(p22;q23) MLLT3-MLL,
t(11; 10), inv(3), inv(9), NPM1 mutated and unspeci-
fied AML (Figure 4A, B). Of the 121 AML patients stu-
died, only 12 samples did not reach this cut off, of which
6 (one inv(3), and 5 complex AML cases) presented with
clear hypermethylation compared to controls but >40%
methylation which may reflect a lower blast count
(Additional file 2: Table S1 and Additional file 3: Table S2).
In contrast, only 2 samples had hypermethylation at the
Figure 3 Histone ChIP in leukocytes and leukemia cell lines. The histone modification signature determined by ChIP-seq for (A) CD34+ and
CD15+ cells. The levels of precipitation are comparable as the y-axis is limited to 50 reads for all tracks. The positions of the subsequent PCR
amplicons used for ChIP are indicated. (B) ChIP specifically targeting the 5′ WT1 interval in normal leukocytes and myeloid derived cancer cell
lines (C) K562 and (D) NB4. qPCR analysis with primers designed to the WT1 and AWT1 promoters performed on immunoprecipitated fractions
and mock IPs. Graphs represent the percentage precipitation relative to input chromatin (mean values ± SEM).
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analysis revealed that the hypermethylation status of the
AWT1 promoter is an excellent marker, with a positive
predictive value (PPV) of 100%, indicating that this marker
can correctly detect and classify healthy individual from
those with AML. The sensitivity and negative predictive
value (NPV) are 86.1% and 89.4% respectively (Additional
file 2: Table S3).
Methylation analysis in other primary hematological
malignancies
We extended our methylation analysis to other forms of
hematological cancers. Similar to AML, chronic myeloid
leukemia cases with BCR-ABL translocations had unme-
thylated WT1 promoters and AWT1 hypermethylation,
however, polycythaemia vera and essential thrombocyth-
aemia samples had methylation profiles indistinguishable
from normal leukocyte controls. In samples classified with
B-cell t(9:22) BCR/ABL, t(4:11) MLL/AFF1, t(12:21) TEL/
AML1 and T-cell lymphoblastic leukemias or follicularand Burkitt lymphomas we identified very variable methy-
lation at the promoters, which was often significantly dif-
ferent from normal controls but not reaching the defined
40% methylation cut-off (Figure 4A, C).
AWT1 hypermethylation discriminates AML patients
who relapse from those achieving complete remission
after SCT
Relapse and progression remain the main causes of
treatment failure in patients with AML after undergoing
allogeneic SCT and often presents as refractory disease.
Numerous reports have shown that ~ 90% of patients
with AML show WT1 overexpression, therefore, this tran-
script has been proposed as a useful marker for evaluating
MRD after chemotherapy or SCT [13,14]. To determine
whether methylation at the WT1 locus is a useful marker
for disease monitoring we performed pyroseqeuncing for
the WT1 and AWT1 promoters in a series of 9 AML pa-
tients before and after allogeneic SCT for whom WT1 ex-
pression had been previously determined [14]. All patients
Figure 4 WT1/AWT1 methylation profiling in primary hematological cancers. (A) Circular heat map of pyrosequencing results for all samples
analyzed indicating disease classification and underlying mutation or translocation. The inner circle represents the methylation values of the
WT1 CpG promoter and the outer circle the AWT1 promoter. (B) Box plot representing the methylation levels at the AWT1 promoter in normal
leukocytes (NL) and in hematological cancers. (C) Box plots for the WT1 methyaltion profiles in the same sample cohort. The differences between
groups were evaluated using the Mann–Whitney T-test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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initial diagnosis or in pre-SCT bone marrow samples, of
these 5 presented with disease relapse, of which 4 were as-
sociated with high WT1 levels. In 8 cases the AWT1 pro-
moter region was hypermethylated at initial assessment.
During the post-transplantation period, high concordance
between normal WT1 expression levels, AWT1 hyperme-
thylation and remission status was seen in patients. Specif-
ically, those patients who attained complete remission had
WT1 expression below the cut-off, similar to normal con-
trols, and the AWT1 region remained unmethylated. In 4
of the 5 patients who underwent disease relapse showed
overexpression of WT1 and gained methylation at the
AWT1 promoter, sometimes to levels higher than at initial
diagnosis (Figure 5). Interestingly, the patient with low
WT1 expression at relapse maintained the AWT1 pro-
moter in an unmethylated state post-SCT, despite being
hypermethylated at diagnosis. Interestingly the WT1 CpG
island remained unmethylated (<13% methylation) in all
patients and time points (data not shown).
Discussion
Recent studies have illustrated the power of methylation
profiling to identify important cancer-related genes asso-
ciated with the pathogenesis and classification of hema-
tological cancers. For example DBC1 hypermethylation
is a prognostic marker for AML with normal karyotype
[15]. In addition large-scale epigenetic studies have de-
monstrated that aberrant methylation is a hallmark ofspecific leukemia sub-types, often associated with known
translocations or genetic mutations. This is best high-
lighted by the AML hypermethylation signature associ-
ated with IDH1/IDH2 mutations, which disrupt TET2
function [16]. In our current study we observe extreme
hypermethylation of the AWT1 promoter, an epigenetic
mark generally associated with robust gene silencing, in
myeloid-derived hematological cancer cell lines and pri-
mary samples. These results are somewhat surprising as
high expression levels of the various WT1 transcripts are
frequently observed in AML [17,18], a scenario that is
normally mutually exclusive with abundant promoter
methylation.
Loss-of-function mutations in TET2, an enzyme that
converts 5mC to 5hmC have been observed in ~8% of
AML cases [19]. Interrogation of the mutation status of
TET2 in the Human Cancer Genome database revealed
that Jurkat was the only cell in our panel that had patho-
logical changes (p.Q831H). This suggests that absence of
demethylation by mutated TET2 is not associated with
the observed AWT1 hypermethylation.
Previous studies in gliomas and breast tumors have
also revealed, contrary to expectation, a high frequency
of WT1 expressing samples with promoter (CpG island
188) hypermethylation [20,21]. Interestingly one study
assessed the affect of 5-aza-deoxycytidine onWT1 expres-
sion and observed that despite decreases in methylation
there was not a concomitant change in WT1 expres-
sion [21]. Interestingly exposing the KG1A cell line to
Figure 5 Time-course of AWT1 methylation after SCT. Evolution of AWT1 methylation and total WT1 expression in (A) patients who relapsed
post-SCT (n = 5) and (B) patients in complete remission (n = 4). Black lines represent expression levels relative to the K562 cell line, with the
dashed black lines representing the pathological thresholds for expression (0.55% of K562). The grey lines represent the methylation range
observed in controls (14.6% ± 3 SD).
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the AWT1 promoter but only a modest doubling in
expression levels (Additional file 4: Figure S2). Des-
pite being a specific cancer marker, the tumor-specific
methylation at this promoter interval appears to be
inconsequential to gene transcription and that other
mechanism regulate expression. This implies that when
interpreting DNA methylation patterns both cellular con-
text and the genomic position of the CpG sites must be
taken into consideration.
Our results in cell lines imply that the WT1 and
AWT1 isoforms are co-regulated, suggesting they share
cis-acting regulatory elements. Recently an enhancer re-
gion located ~1 kb past the shared 3′UTR has been
identified and shown to bind the myeloid-specific tran-
scription factor GATA-2 [22], with abundant expression
of GATA-2 and WT1 in AML being associated with bad
prognosis [23]. An expression analysis in the 26 of the
hematological cancer cell lines and 53 primary AML
samples revealed GATA-2 and WT1/AWT1 co-expressed
in 96% cases (51/56) consistent with this mechanism be-
ing a regulator of expression at the locus (Additional file
5: Figure S3). Computational analysis of the ENCODE
dataset reveals that the GATA-2 site is enriched for
H3K27ac, a histone modification frequently associated
with enhancer elements [24]. This chromatin state may
therefore be permissive to chromatin looping betweenthis enhancer and the WT1 promoter region. Interroga-
tion of the Chromatin Interaction Analysis Paired–End
Tags (ChIA-PET) dataset in K562 cells suggests there is a
strong physical association between these two genomic
elements facilitated by POLII (Additional file 5: Figure S3).
Mutations in WT1 have been reported in 6-10% of
AML cases, 20% of biphenotypic leukemias and sporadic
T-cell acute lymphoblastic leukemias (T-ALL) [25-27].
This is a similar frequency to that found in sporadic
Wilm’s tumors [28,29]. In AML and T-ALL cases with
heterozygous mutations, expression analyses have dem-
onstrated biallelic expression of both the mutated and
wild-type WT1 alleles consistent with our observations
that the WT1 and AWT1 transcripts are not subject to
genomic imprinting [27,30]. Interestingly, direct sequen-
cing of all exons of the WT1 gene in our panel of cell
lines identified only one mutation in addition to known
polymorphisms, an A > G nonsense mutation in exon 7
(p.R369*) of the non-expressing U937 cell line.
Despite the plethora of research on the role of WT1 in
leukemia, it remains unclear if the abundant WT1 levels
represent ectopic expression during carcinogenesis or
simply reflects the arrested differentiation during early
hematopoiesis, since most AML have an immature phe-
notype. However, the hypermethylation observed at this
domain is associated with the tumorgenic changes since
methylation at the WT1 and AWT1 CpG islands is never
Guillaumet-Adkins et al. Journal of Hematology & Oncology 2014, 7:4 Page 9 of 11
http://www.jhoonline.org/content/7/1/4observed in any normal hematopoietic cell type or CD34+
stem cells.
The discovery of novel molecular markers that are
highly specific and sensitive will improve strategies for
both detecting and classifying tumor types, but also in
the management of cancer by monitoring a tumors re-
sponse to novel therapies. Here we show that using a
cut-off of >40% methylation at the AWT1 promoter, the
PPV for our assay in AML is 100%, indicating that the
analysis can correctly detect and classifies a healthy in-
dividual. The sensitivity and NPV are 86.1% and 89.4%
respectively, making this an ideal marker to correctly clas-
sify AML compared to controls. It must be noted, how-
ever, that when assessing all hematological malignancies
together, hypermethylation of the AWT1 promoter it does
not perform well as a diagnostic factor for unspecified leu-
kemias/lymphomas (sensitivity 47%; specificity 100%; PPV
100%; NPV 43.6%) (Additional file 2: Table S3). Therefore
quantitating AWT1 hypermethyaltion is ideally suited to
monitor MRD in which the diagnosis of AML has already
been performed, and the recurrence of the disease during
remission needs to be accurately monitored as revealed by
our analysis of patients undergoing allogeneic SCT.
Conclusion
In summary, differences in methylation patterns among
tumors may be correlated with clinical features of pa-
tients and can serve as markers in cancer classification.
Here we describe a methylation signature of the AWT1
promoter CpG island that is a promising marker for
classifying myeloid-derived leukemias. When compared
to the results of other well-characterized methylation
markers in additional forms of cancer (i.e. MGMT in glio-
blastomas and GSTP1 in prostate cancers) [31,32] the
outcomes are extremely encouraging and further work
on larger cohorts, maybe in combination with other
leukemia-specific methylation markers, are required to
confirm if our observations can be useful in a clinical
setting. It remains to be determined what mechanisms
are responsible for the correlated up-regulation of WT1
and AWT1 expression, with DNA methylation, micro-
RNA, enhancer activation or even utilization of an un-
identified enhancing long non-coding RNA all possibly
having an influence [33].
Methods
Patient samples and cell lines
DNA was extracted from frozen peripheral blood and/
or bone marrow samples from 356 patients at diagnosis
and 102 control peripheral blood samples. For 9 indi-
viduals, we also had samples from multiple time points
following SCT. Full clinical classification of the cohort
can be found in Additional file 2: Table S1 and Additional
file 3: Table S2. In addition, DNA and RNA were isolatedfrom 28 derived from various hematological malignancies
along with CD15+ (neutrophils and monocytes), CD19+
(B -cells) and CD3+ (T-lymphocyte) cell fractions. The cell
lines were purchased directly from the ATCC or DSMZ
cell line repositories and were grown in DMEM media
with 10% heat inactivated fetal calf serum supplemented
with 50 U/ml penicillin and 50 μg/ml streptomycin. In
addition all cell lines were routinely tested to ensure they
were free of mycoplasm contamination. These studies
were approved by the ethical committee of Bellvitge Insti-
tute for Biomedical Research/CEIC (PR159/08) and all pa-
tients gave informed consent.
Dataset analysis
To determine the epigenetic landscape of the WT1 region
we analyzed publically available H3K4me3, H3K9me3 and
H3K27me3 ChIP-seq datasets and whole genome bisul-
phite sequencing (WGBS) methylomes for CD34+ and
three leukocytes. All data analyses were performed using
in-house R-scripts. We subsequently targeted specific re-
gions of interest using bisulphite PCR.
Methylation analysis
Approximately 50 ng of bisulphite converted DNA was
used for each bisulphite PCR or pyrosequencing reaction
(for primer sequences see Additional file 2: Table S4).
To differentiate between 5′-hydroxymethylation (5hmC)
and 5-methylcytosine (5mC) we utilized methylated
DNA immunoprecipitations (meDIP) with a specific
5hmC or 5mC antibodies (Diagenode, Liege, Belgium)
and the Quest 5hmC Glucosyltransferase Detection
KitTM (Zymo).
Chromatin immunoprecipitations
For ChIP, 100 μg of chromatin was used for each immu-
noprecipitation reaction with Protein A Agarose/Salmon
Sperm DNA and specific antibody raised against vari-
ous post-translational histone H3 or H4 modifications
(H3K4me2 Millipore 07–030; H3K4me3 Millipore 07–
473; H3K9ac Cell Signalling 9671; H3K9me2 Millipore
07–441; H3K9me3 Abcam 8898; H4K20me3 Millipore
07–463; H3K27me3 Millipore 07–449). The levels of im-
munoprecipitated chromatin at specific regions were de-
termined by qPCR using an Applied Biosystems 7900 Fast
real-time PCR machine, using SYBR Green and IP levels
were compared to Input and the results expressed as per-
centage of total input material.
Quantitative RT-PCR
The levels of various WT1 transcripts were assessed
using qRT-PCR. All PCR amplifications were run in trip-
licate on a 7900 Fast real-time PCR machine (Applied
Biosystems) following the manufacturers’ protocol. All
primers were optimized using SYBR Green (Additional
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http://www.jhoonline.org/content/7/1/4file 2: Table S4 for primer sequences) and melt curve
analysis to ensure that amplicons were specific and free
of primer-dimer products. Thermal cycle parameters in-
cluded Taq polymerase activation at 95°C for 10 min for
1 cycle, repetitive denaturation at 95°C for 15 sec, and
annealing at 60°C for 1 min for 40 cycles. All resulting
triplicate cycle threshold (Ct) values had to be with 1 Ct
of each other. The quantitative values for each triplicate
were determined as a ratio with the level of β-Actin ex-
pression that was measured in the same sample, and
then averaged to provide relative expression values. A
cDNA mix of all cell lines and controls was used as an
expression calibrator.Western blot analysis
We extracted nuclear and cytoplasm protein fractions
from cell lines for western blot using the NE-PER Nuclear
and Cytoplasmic Extraction kit (Thermo Scientific). SDS-
PAGE gel electrophoresis and western blotting was per-
formed as standard. To determine the cellular localization
of proteins we incubated resulting membranes with
primary antibodies against WT1 (Santa Cruz sc-192),
β-Tubulin (Abcam ab6046) or Nucleolin (Santa Cruz
sc-8031). Washed membranes were incubated with corre-
sponding peroxidase-conjugated secondary antibody. The
immunoreactive proteins were visualized using the ECL
Western blotting detection kit (Amersham Biosciences).Additional files
Additional file 1: Figure S1. (A) Confirmation of imprinted methylation
at the H19-DMR in peripheral leukocytes. (B) Bisulphite PCR analysis of
the WT1 promoter interval in cell lines derived from hematological
cancers other than AML.
Additional file 2: Table S1. Characterization of hematological
neoplasms according to cytogenetic aberrations. Table S3. Specificity of
AWT1/WT1 hypermethylation as a biomarker. Table S4. The PCR primer
sequences used in this study.
Additional file 3: Table S2. Characterization of hematological
neoplasms using WHO classification with information on age and sex of
the patients (if data available). The methylation values obtained following
pyrosequencing for the WT1 and AWT1 promoters are also given.
Additional file 4: Figure S2. (A) Methylation values of repetitive DNA
elements in the KG1A cell lines treated with different concentrations of
Decitabine. (B) The methylation values for WT1 and AWT1 promoters and
(C) qRT-PCR for WT1, AWT1 and WT1-AS transcripts following Decitabine
treatment.
Additional file 5: Figure S3. (A) Map of the WT1 locus showing POLII
mediated ChIA-PET interactions between the GATA-2 enhancer and the
WT1 promoter interval. (B) Abundance of the GATA-2 transcription factor
in hematological cancer cell lines as determined by qRT-PCR.Abbreviations
WT1: Wilms tumour 1 gene; AML: Acute myeloid leukemia; MRD: Minimal
residual disease; SCT: Stem cell transplant; RT-PCR: Reverse transcriptase
polymerase chain reaction; ChIP: Chromatin immunoprecipitation; 5hmC:
5- hydroxymethylation; 5mC: 5-methylcytosine.Competing interests
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